Harris A W, Misiewicz J J, Bardhan K D, Levi S, O'Morain C, Cooper B T, Kerr G D, Dixon M F, Langworthy H, Piper D
Central Middlesex Hospital, London, UK.
Aliment Pharmacol Ther. 1998 Aug;12(8):741-5. doi: 10.1046/j.1365-2036.1998.00362.x.
A number of clinical studies have assessed the efficacy of short-term twice-daily Helicobacter pylori eradication regimens but few have investigated the proportion of patients in whom duodenal ulcer disease was healed with these regimens.
To compare the safety and efficacy of four 1-week H. pylori eradication regimens in the healing of H. pylori associated duodenal ulcer disease.
Following endoscopic confirmation of duodenal ulcer disease and a positive CLO test, patients underwent a 13C-urea breath test to confirm H. pylori status. Treatment with one of four regimens: LAC, LAM, LCM or OAM, where L is lansoprazole 30 mg b.d., A is amoxycillin 1 g b.d., M is metronidazole 400 mg b.d., C is clarithromycin 250 mg b.d., and O is omeprazole 20 mg b.d., was assigned randomly to those patients who were H. pylori positive, with 62 (LAC), 64 (LAM), 61 (LCM) and 75 (OAM) patients in each treatment group. Follow-up breath tests and endoscopies were performed at least 28 days after the end of treatment.
Duodenal ulcer disease was healed 28 days after treatment in 53/62 (85.5%) patients who were treated with LAC, 52/64 (81.3%) of patients treated with LAM, 49/61 (80.3%) of patients treated with LCM and 60/75 (80.0%) of patients treated with OAM (intention-to-treat analysis, n = 262, assumed unhealed if no follow-up endoscopy was performed). All the treatments were of similar efficacy (P = 0.85, chi-squared test) with regard to the healing of duodenal ulcer disease.
The four 1-week treatment regimens were equally effective in healing H. pylori associated duodenal ulcer disease.
多项临床研究评估了每日两次的短期幽门螺杆菌根除方案的疗效,但很少有研究调查采用这些方案治疗十二指肠溃疡疾病的患者比例。
比较四种为期1周的幽门螺杆菌根除方案在治疗幽门螺杆菌相关性十二指肠溃疡疾病中的安全性和疗效。
在内镜检查确诊十二指肠溃疡疾病且CLO试验呈阳性后,患者接受13C-尿素呼气试验以确认幽门螺杆菌感染状况。将四种方案之一(LAC、LAM、LCM或OAM,其中L为兰索拉唑30mg,每日两次;A为阿莫西林1g,每日两次;M为甲硝唑400mg,每日两次;C为克拉霉素250mg,每日两次;O为奥美拉唑20mg,每日两次)随机分配给幽门螺杆菌阳性患者,每个治疗组分别有62例(LAC)、64例(LAM)、61例(LCM)和75例(OAM)患者。在治疗结束后至少28天进行随访呼气试验和内镜检查。
接受LAC治疗的患者中,53/62(85.5%)在治疗28天后十二指肠溃疡疾病愈合;接受LAM治疗的患者中,52/64(81.3%)愈合;接受LCM治疗的患者中,49/61(80.3%)愈合;接受OAM治疗的患者中,60/75(80.0%)愈合(意向性分析,n = 262,若未进行随访内镜检查则假定未愈合)。就十二指肠溃疡疾病的愈合而言,所有治疗的疗效相似(P = 0.85,卡方检验)。
四种为期1周的治疗方案在治疗幽门螺杆菌相关性十二指肠溃疡疾病方面同样有效。